株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

禁煙 - パイプライン分析

Smoking Cessation - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 232840
出版日 ページ情報 英文 110 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
禁煙 - パイプライン分析 Smoking Cessation - Pipeline Review, H2 2015
出版日: 2015年08月31日 ページ情報: 英文 110 Pages
概要

当レポートでは、禁煙関連の医薬品の開発状況について調査しており、パイプライン製品の概要、治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

禁煙の概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Aradigm Corporation
  • Arena Pharmaceuticals, Inc.
  • Astraea Therapeutics, LLC
  • Bioprojet SCR
  • Embera NeuroTherapeutics, Inc.
  • FORUM Pharmaceuticals Inc.
  • GlaxoSmithKline plc
  • Invion Limited
  • Johnson & Johnson
  • Marinus Pharmaceuticals, Inc.
  • NAL Pharmaceuticals Ltd.
  • Pfizer Inc.
  • Royalty Pharma
  • Selecta Biosciences, Inc.
  • Targacept, Inc.
  • Zynerba Pharmaceuticals, Inc.

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (oxazepam + metyrapone)
  • Anatabine
  • ARD-1600
  • BP-1.4979
  • Drugs to Inhibit FAAH for CNS Disorders
  • encenicline hydrochloride
  • ganaxolone
  • GSK-598809
  • lorcaserin hydrochloride
  • nadolol
  • NIC7-DT
  • nicotine
  • nicotine
  • Nicotine Vaccine
  • PF-05402536
  • PF-06413367
  • SEL-068
  • Small Molecule for Smoking Cessation
  • Small Molecule for Smoking Cessation and Appetite Suppression
  • Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation
  • Small Molecule to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation
  • Small Molecules to Agonize Alpha 4 Neuronal Nicotinic Receptor for Smoking Cessation
  • Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6981IDB

Summary

Global Markets Direct's, 'Smoking Cessation - Pipeline Review, H2 2015', provides an overview of the Smoking Cessation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Smoking Cessation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smoking Cessation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Smoking Cessation
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Smoking Cessation and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Smoking Cessation pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Smoking Cessation
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Smoking Cessation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Smoking Cessation Overview
  • Therapeutics Development
    • Pipeline Products for Smoking Cessation - Overview
    • Pipeline Products for Smoking Cessation - Comparative Analysis
  • Smoking Cessation - Therapeutics under Development by Companies
  • Smoking Cessation - Therapeutics under Investigation by Universities/Institutes
  • Smoking Cessation - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Smoking Cessation - Products under Development by Companies
  • Smoking Cessation - Products under Investigation by Universities/Institutes
  • Smoking Cessation - Companies Involved in Therapeutics Development
    • Aradigm Corporation
    • Arena Pharmaceuticals, Inc.
    • Astraea Therapeutics, LLC
    • Bioprojet SCR
    • Catalyst Biosciences, Inc.
    • CoMentis, Inc.
    • Embera NeuroTherapeutics, Inc.
    • FORUM Pharmaceuticals Inc.
    • GlaxoSmithKline Plc
    • Invion Limited
    • Johnson & Johnson
    • NAL Pharmaceuticals Ltd.
    • Pfizer Inc.
    • Pivot Pharmaceuticals Inc
    • Royalty Pharma
    • Selecta Biosciences, Inc.
    • Zynerba Pharmaceuticals, Inc.
  • Smoking Cessation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (oxazepam + metyrapone) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Anatabine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARD-1600 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BP-1.4979 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit FAAH for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • encenicline hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSK-598809 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GTS-21 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JNJ-39393406 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lorcaserin hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nadolol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NFL-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NIC7-DT - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nicotine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nicotine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Nicotine Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-05402536 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-06413367 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SEL-068 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Smoking Cessation and Appetite Suppression - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize Alpha 4 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Smoking Cessation - Recent Pipeline Updates
  • Smoking Cessation - Dormant Projects
  • Smoking Cessation - Discontinued Products
  • Smoking Cessation - Product Development Milestones
    • Featured News & Press Releases
      • Jun 29, 2015: Invion completes dosing in key phase II clinical trial of oral INV102 in smoking cessation
      • Feb 02, 2015: Invion completes enrolment in its phase II trial of oral INV102 (nadolol) in smoking cessation
      • Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation
      • Nov 04, 2014: Lorcaserin Meets Primary Endpoint And Confirms Proof-Of-Concept As Potential Aid For Smoking Cessation In Investigational Phase II Clinical Study
      • Nov 03, 2014: Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation
      • Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform
      • May 09, 2014: Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ (lorcaserin HCl) CIV by 50%
      • Jan 29, 2014: FDA clears path for "Smoking Cessation" clinical trial of INV102 (nadolol)
      • Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial
      • Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Smoking Cessation, H2 2015
  • Number of Products under Development for Smoking Cessation - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Smoking Cessation - Pipeline by Aradigm Corporation, H2 2015
  • Smoking Cessation - Pipeline by Arena Pharmaceuticals, Inc., H2 2015
  • Smoking Cessation - Pipeline by Astraea Therapeutics, LLC, H2 2015
  • Smoking Cessation - Pipeline by Bioprojet SCR, H2 2015
  • Smoking Cessation - Pipeline by Catalyst Biosciences, Inc., H2 2015
  • Smoking Cessation - Pipeline by CoMentis, Inc., H2 2015
  • Smoking Cessation - Pipeline by Embera NeuroTherapeutics, Inc., H2 2015
  • Smoking Cessation - Pipeline by FORUM Pharmaceuticals Inc., H2 2015
  • Smoking Cessation - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Smoking Cessation - Pipeline by Invion Limited, H2 2015
  • Smoking Cessation - Pipeline by Johnson & Johnson, H2 2015
  • Smoking Cessation - Pipeline by NAL Pharmaceuticals Ltd., H2 2015
  • Smoking Cessation - Pipeline by Pfizer Inc., H2 2015
  • Smoking Cessation - Pipeline by Pivot Pharmaceuticals Inc, H2 2015
  • Smoking Cessation - Pipeline by Royalty Pharma, H2 2015
  • Smoking Cessation - Pipeline by Selecta Biosciences, Inc., H2 2015
  • Smoking Cessation - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Smoking Cessation Therapeutics - Recent Pipeline Updates, H2 2015
  • Smoking Cessation - Dormant Projects, H2 2015
  • Smoking Cessation - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Smoking Cessation, H2 2015
  • Number of Products under Development for Smoking Cessation - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top